COVID-19 Impact on Global Inactivated Vaccine, Market Insights and Forecast to 2026
Inactivated Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Inactivated Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Inactivated Vaccine market is segmented into
The Inactivated Vaccine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Inactivated Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Inactivated Vaccine Market Share Analysis
Inactivated Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Inactivated Vaccine business, the date to enter into the Inactivated Vaccine market, Inactivated Vaccine product introduction, recent developments, etc.
The major vendors covered:
Segment by Type, the Inactivated Vaccine market is segmented into
- Children
- Adult
- Hospital
- Medical Center
The Inactivated Vaccine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Inactivated Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Inactivated Vaccine Market Share Analysis
Inactivated Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Inactivated Vaccine business, the date to enter into the Inactivated Vaccine market, Inactivated Vaccine product introduction, recent developments, etc.
The major vendors covered:
- Astellas Pharma (Japan)
- CSL Limited (Australia)
- Emergent BioSolutions (U.S.)
- GlaxoSmithKline (U.K.)
- Johnson & Johnson (U.S.)
- MedImmune (U.S.)
- Merck & Co (U.S.)
- Pfizer (U.S.)
- Sanofi Pasteur (France)
- Serum Institute of India Pvt (India)
1 STUDY COVERAGE
1.1 Inactivated Vaccine Product Introduction
1.2 Market Segments
1.3 Key Inactivated Vaccine Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Inactivated Vaccine Market Size Growth Rate by Type
1.4.2 Children
1.4.3 Adult
1.5 Market by Application
1.5.1 Global Inactivated Vaccine Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Medical Center
1.6 Coronavirus Disease 2019 (Covid-19): Inactivated Vaccine Industry Impact
1.6.1 How the Covid-19 is Affecting the Inactivated Vaccine Industry
1.6.1.1 Inactivated Vaccine Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Inactivated Vaccine Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Inactivated Vaccine Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Inactivated Vaccine Market Size Estimates and Forecasts
2.1.1 Global Inactivated Vaccine Revenue 2015-2026
2.1.2 Global Inactivated Vaccine Sales 2015-2026
2.2 Inactivated Vaccine Market Size by Region: 2020 Versus 2026
2.2.1 Global Inactivated Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Inactivated Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL INACTIVATED VACCINE COMPETITOR LANDSCAPE BY PLAYERS
3.1 Inactivated Vaccine Sales by Manufacturers
3.1.1 Inactivated Vaccine Sales by Manufacturers (2015-2020)
3.1.2 Inactivated Vaccine Sales Market Share by Manufacturers (2015-2020)
3.2 Inactivated Vaccine Revenue by Manufacturers
3.2.1 Inactivated Vaccine Revenue by Manufacturers (2015-2020)
3.2.2 Inactivated Vaccine Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Inactivated Vaccine Revenue in 2019
3.2.5 Global Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Inactivated Vaccine Price by Manufacturers
3.4 Inactivated Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Inactivated Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Inactivated Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Inactivated Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Inactivated Vaccine Market Size by Type (2015-2020)
4.1.1 Global Inactivated Vaccine Sales by Type (2015-2020)
4.1.2 Global Inactivated Vaccine Revenue by Type (2015-2020)
4.1.3 Inactivated Vaccine Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Inactivated Vaccine Market Size Forecast by Type (2021-2026)
4.2.1 Global Inactivated Vaccine Sales Forecast by Type (2021-2026)
4.2.2 Global Inactivated Vaccine Revenue Forecast by Type (2021-2026)
4.2.3 Inactivated Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Inactivated Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Inactivated Vaccine Market Size by Application (2015-2020)
5.1.1 Global Inactivated Vaccine Sales by Application (2015-2020)
5.1.2 Global Inactivated Vaccine Revenue by Application (2015-2020)
5.1.3 Inactivated Vaccine Price by Application (2015-2020)
5.2 Inactivated Vaccine Market Size Forecast by Application (2021-2026)
5.2.1 Global Inactivated Vaccine Sales Forecast by Application (2021-2026)
5.2.2 Global Inactivated Vaccine Revenue Forecast by Application (2021-2026)
5.2.3 Global Inactivated Vaccine Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Inactivated Vaccine by Country
6.1.1 North America Inactivated Vaccine Sales by Country
6.1.2 North America Inactivated Vaccine Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Inactivated Vaccine Market Facts & Figures by Type
6.3 North America Inactivated Vaccine Market Facts & Figures by Application
7 EUROPE
7.1 Europe Inactivated Vaccine by Country
7.1.1 Europe Inactivated Vaccine Sales by Country
7.1.2 Europe Inactivated Vaccine Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Inactivated Vaccine Market Facts & Figures by Type
7.3 Europe Inactivated Vaccine Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Inactivated Vaccine by Region
8.1.1 Asia Pacific Inactivated Vaccine Sales by Region
8.1.2 Asia Pacific Inactivated Vaccine Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Inactivated Vaccine Market Facts & Figures by Type
8.3 Asia Pacific Inactivated Vaccine Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Inactivated Vaccine by Country
9.1.1 Latin America Inactivated Vaccine Sales by Country
9.1.2 Latin America Inactivated Vaccine Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Inactivated Vaccine Market Facts & Figures by Type
9.3 Central & South America Inactivated Vaccine Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Inactivated Vaccine by Country
10.1.1 Middle East and Africa Inactivated Vaccine Sales by Country
10.1.2 Middle East and Africa Inactivated Vaccine Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Type
10.3 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
11.2 CSL Limited (Australia)
11.2.1 CSL Limited (Australia) Corporation Information
11.2.2 CSL Limited (Australia) Description, Business Overview and Total Revenue
11.2.3 CSL Limited (Australia) Sales, Revenue and Gross Margin (2015-2020)
11.2.4 CSL Limited (Australia) Inactivated Vaccine Products Offered
11.2.5 CSL Limited (Australia) Recent Development
11.3 Emergent BioSolutions (U.S.)
11.3.1 Emergent BioSolutions (U.S.) Corporation Information
11.3.2 Emergent BioSolutions (U.S.) Description, Business Overview and Total Revenue
11.3.3 Emergent BioSolutions (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Emergent BioSolutions (U.S.) Inactivated Vaccine Products Offered
11.3.5 Emergent BioSolutions (U.S.) Recent Development
11.4 GlaxoSmithKline (U.K.)
11.4.1 GlaxoSmithKline (U.K.) Corporation Information
11.4.2 GlaxoSmithKline (U.K.) Description, Business Overview and Total Revenue
11.4.3 GlaxoSmithKline (U.K.) Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline (U.K.) Inactivated Vaccine Products Offered
11.4.5 GlaxoSmithKline (U.K.) Recent Development
11.5 Johnson & Johnson (U.S.)
11.5.1 Johnson & Johnson (U.S.) Corporation Information
11.5.2 Johnson & Johnson (U.S.) Description, Business Overview and Total Revenue
11.5.3 Johnson & Johnson (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Johnson & Johnson (U.S.) Inactivated Vaccine Products Offered
11.5.5 Johnson & Johnson (U.S.) Recent Development
11.6 MedImmune (U.S.)
11.6.1 MedImmune (U.S.) Corporation Information
11.6.2 MedImmune (U.S.) Description, Business Overview and Total Revenue
11.6.3 MedImmune (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.6.4 MedImmune (U.S.) Inactivated Vaccine Products Offered
11.6.5 MedImmune (U.S.) Recent Development
11.7 Merck & Co (U.S.)
11.7.1 Merck & Co (U.S.) Corporation Information
11.7.2 Merck & Co (U.S.) Description, Business Overview and Total Revenue
11.7.3 Merck & Co (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Merck & Co (U.S.) Inactivated Vaccine Products Offered
11.7.5 Merck & Co (U.S.) Recent Development
11.8 Pfizer (U.S.)
11.8.1 Pfizer (U.S.) Corporation Information
11.8.2 Pfizer (U.S.) Description, Business Overview and Total Revenue
11.8.3 Pfizer (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Pfizer (U.S.) Inactivated Vaccine Products Offered
11.8.5 Pfizer (U.S.) Recent Development
11.9 Sanofi Pasteur (France)
11.9.1 Sanofi Pasteur (France) Corporation Information
11.9.2 Sanofi Pasteur (France) Description, Business Overview and Total Revenue
11.9.3 Sanofi Pasteur (France) Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sanofi Pasteur (France) Inactivated Vaccine Products Offered
11.9.5 Sanofi Pasteur (France) Recent Development
11.10 Serum Institute of India Pvt (India)
11.10.1 Serum Institute of India Pvt (India) Corporation Information
11.10.2 Serum Institute of India Pvt (India) Description, Business Overview and Total Revenue
11.10.3 Serum Institute of India Pvt (India) Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Serum Institute of India Pvt (India) Inactivated Vaccine Products Offered
11.10.5 Serum Institute of India Pvt (India) Recent Development
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Inactivated Vaccine Market Estimates and Projections by Region
12.1.1 Global Inactivated Vaccine Sales Forecast by Regions 2021-2026
12.1.2 Global Inactivated Vaccine Revenue Forecast by Regions 2021-2026
12.2 North America Inactivated Vaccine Market Size Forecast (2021-2026)
12.2.1 North America: Inactivated Vaccine Sales Forecast (2021-2026)
12.2.2 North America: Inactivated Vaccine Revenue Forecast (2021-2026)
12.2.3 North America: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
12.3 Europe Inactivated Vaccine Market Size Forecast (2021-2026)
12.3.1 Europe: Inactivated Vaccine Sales Forecast (2021-2026)
12.3.2 Europe: Inactivated Vaccine Revenue Forecast (2021-2026)
12.3.3 Europe: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Inactivated Vaccine Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Inactivated Vaccine Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Inactivated Vaccine Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Inactivated Vaccine Market Size Forecast by Region (2021-2026)
12.5 Latin America Inactivated Vaccine Market Size Forecast (2021-2026)
12.5.1 Latin America: Inactivated Vaccine Sales Forecast (2021-2026)
12.5.2 Latin America: Inactivated Vaccine Revenue Forecast (2021-2026)
12.5.3 Latin America: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Inactivated Vaccine Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Inactivated Vaccine Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Inactivated Vaccine Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Inactivated Vaccine Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Inactivated Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Inactivated Vaccine Product Introduction
1.2 Market Segments
1.3 Key Inactivated Vaccine Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Inactivated Vaccine Market Size Growth Rate by Type
1.4.2 Children
1.4.3 Adult
1.5 Market by Application
1.5.1 Global Inactivated Vaccine Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Medical Center
1.6 Coronavirus Disease 2019 (Covid-19): Inactivated Vaccine Industry Impact
1.6.1 How the Covid-19 is Affecting the Inactivated Vaccine Industry
1.6.1.1 Inactivated Vaccine Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Inactivated Vaccine Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Inactivated Vaccine Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Inactivated Vaccine Market Size Estimates and Forecasts
2.1.1 Global Inactivated Vaccine Revenue 2015-2026
2.1.2 Global Inactivated Vaccine Sales 2015-2026
2.2 Inactivated Vaccine Market Size by Region: 2020 Versus 2026
2.2.1 Global Inactivated Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Inactivated Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL INACTIVATED VACCINE COMPETITOR LANDSCAPE BY PLAYERS
3.1 Inactivated Vaccine Sales by Manufacturers
3.1.1 Inactivated Vaccine Sales by Manufacturers (2015-2020)
3.1.2 Inactivated Vaccine Sales Market Share by Manufacturers (2015-2020)
3.2 Inactivated Vaccine Revenue by Manufacturers
3.2.1 Inactivated Vaccine Revenue by Manufacturers (2015-2020)
3.2.2 Inactivated Vaccine Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Inactivated Vaccine Revenue in 2019
3.2.5 Global Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Inactivated Vaccine Price by Manufacturers
3.4 Inactivated Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Inactivated Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Inactivated Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Inactivated Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Inactivated Vaccine Market Size by Type (2015-2020)
4.1.1 Global Inactivated Vaccine Sales by Type (2015-2020)
4.1.2 Global Inactivated Vaccine Revenue by Type (2015-2020)
4.1.3 Inactivated Vaccine Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Inactivated Vaccine Market Size Forecast by Type (2021-2026)
4.2.1 Global Inactivated Vaccine Sales Forecast by Type (2021-2026)
4.2.2 Global Inactivated Vaccine Revenue Forecast by Type (2021-2026)
4.2.3 Inactivated Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Inactivated Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Inactivated Vaccine Market Size by Application (2015-2020)
5.1.1 Global Inactivated Vaccine Sales by Application (2015-2020)
5.1.2 Global Inactivated Vaccine Revenue by Application (2015-2020)
5.1.3 Inactivated Vaccine Price by Application (2015-2020)
5.2 Inactivated Vaccine Market Size Forecast by Application (2021-2026)
5.2.1 Global Inactivated Vaccine Sales Forecast by Application (2021-2026)
5.2.2 Global Inactivated Vaccine Revenue Forecast by Application (2021-2026)
5.2.3 Global Inactivated Vaccine Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Inactivated Vaccine by Country
6.1.1 North America Inactivated Vaccine Sales by Country
6.1.2 North America Inactivated Vaccine Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Inactivated Vaccine Market Facts & Figures by Type
6.3 North America Inactivated Vaccine Market Facts & Figures by Application
7 EUROPE
7.1 Europe Inactivated Vaccine by Country
7.1.1 Europe Inactivated Vaccine Sales by Country
7.1.2 Europe Inactivated Vaccine Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Inactivated Vaccine Market Facts & Figures by Type
7.3 Europe Inactivated Vaccine Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Inactivated Vaccine by Region
8.1.1 Asia Pacific Inactivated Vaccine Sales by Region
8.1.2 Asia Pacific Inactivated Vaccine Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Inactivated Vaccine Market Facts & Figures by Type
8.3 Asia Pacific Inactivated Vaccine Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Inactivated Vaccine by Country
9.1.1 Latin America Inactivated Vaccine Sales by Country
9.1.2 Latin America Inactivated Vaccine Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Inactivated Vaccine Market Facts & Figures by Type
9.3 Central & South America Inactivated Vaccine Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Inactivated Vaccine by Country
10.1.1 Middle East and Africa Inactivated Vaccine Sales by Country
10.1.2 Middle East and Africa Inactivated Vaccine Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Type
10.3 Middle East and Africa Inactivated Vaccine Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
11.2 CSL Limited (Australia)
11.2.1 CSL Limited (Australia) Corporation Information
11.2.2 CSL Limited (Australia) Description, Business Overview and Total Revenue
11.2.3 CSL Limited (Australia) Sales, Revenue and Gross Margin (2015-2020)
11.2.4 CSL Limited (Australia) Inactivated Vaccine Products Offered
11.2.5 CSL Limited (Australia) Recent Development
11.3 Emergent BioSolutions (U.S.)
11.3.1 Emergent BioSolutions (U.S.) Corporation Information
11.3.2 Emergent BioSolutions (U.S.) Description, Business Overview and Total Revenue
11.3.3 Emergent BioSolutions (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Emergent BioSolutions (U.S.) Inactivated Vaccine Products Offered
11.3.5 Emergent BioSolutions (U.S.) Recent Development
11.4 GlaxoSmithKline (U.K.)
11.4.1 GlaxoSmithKline (U.K.) Corporation Information
11.4.2 GlaxoSmithKline (U.K.) Description, Business Overview and Total Revenue
11.4.3 GlaxoSmithKline (U.K.) Sales, Revenue and Gross Margin (2015-2020)
11.4.4 GlaxoSmithKline (U.K.) Inactivated Vaccine Products Offered
11.4.5 GlaxoSmithKline (U.K.) Recent Development
11.5 Johnson & Johnson (U.S.)
11.5.1 Johnson & Johnson (U.S.) Corporation Information
11.5.2 Johnson & Johnson (U.S.) Description, Business Overview and Total Revenue
11.5.3 Johnson & Johnson (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Johnson & Johnson (U.S.) Inactivated Vaccine Products Offered
11.5.5 Johnson & Johnson (U.S.) Recent Development
11.6 MedImmune (U.S.)
11.6.1 MedImmune (U.S.) Corporation Information
11.6.2 MedImmune (U.S.) Description, Business Overview and Total Revenue
11.6.3 MedImmune (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.6.4 MedImmune (U.S.) Inactivated Vaccine Products Offered
11.6.5 MedImmune (U.S.) Recent Development
11.7 Merck & Co (U.S.)
11.7.1 Merck & Co (U.S.) Corporation Information
11.7.2 Merck & Co (U.S.) Description, Business Overview and Total Revenue
11.7.3 Merck & Co (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Merck & Co (U.S.) Inactivated Vaccine Products Offered
11.7.5 Merck & Co (U.S.) Recent Development
11.8 Pfizer (U.S.)
11.8.1 Pfizer (U.S.) Corporation Information
11.8.2 Pfizer (U.S.) Description, Business Overview and Total Revenue
11.8.3 Pfizer (U.S.) Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Pfizer (U.S.) Inactivated Vaccine Products Offered
11.8.5 Pfizer (U.S.) Recent Development
11.9 Sanofi Pasteur (France)
11.9.1 Sanofi Pasteur (France) Corporation Information
11.9.2 Sanofi Pasteur (France) Description, Business Overview and Total Revenue
11.9.3 Sanofi Pasteur (France) Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sanofi Pasteur (France) Inactivated Vaccine Products Offered
11.9.5 Sanofi Pasteur (France) Recent Development
11.10 Serum Institute of India Pvt (India)
11.10.1 Serum Institute of India Pvt (India) Corporation Information
11.10.2 Serum Institute of India Pvt (India) Description, Business Overview and Total Revenue
11.10.3 Serum Institute of India Pvt (India) Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Serum Institute of India Pvt (India) Inactivated Vaccine Products Offered
11.10.5 Serum Institute of India Pvt (India) Recent Development
11.1 Astellas Pharma (Japan)
11.1.1 Astellas Pharma (Japan) Corporation Information
11.1.2 Astellas Pharma (Japan) Description, Business Overview and Total Revenue
11.1.3 Astellas Pharma (Japan) Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Astellas Pharma (Japan) Inactivated Vaccine Products Offered
11.1.5 Astellas Pharma (Japan) Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Inactivated Vaccine Market Estimates and Projections by Region
12.1.1 Global Inactivated Vaccine Sales Forecast by Regions 2021-2026
12.1.2 Global Inactivated Vaccine Revenue Forecast by Regions 2021-2026
12.2 North America Inactivated Vaccine Market Size Forecast (2021-2026)
12.2.1 North America: Inactivated Vaccine Sales Forecast (2021-2026)
12.2.2 North America: Inactivated Vaccine Revenue Forecast (2021-2026)
12.2.3 North America: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
12.3 Europe Inactivated Vaccine Market Size Forecast (2021-2026)
12.3.1 Europe: Inactivated Vaccine Sales Forecast (2021-2026)
12.3.2 Europe: Inactivated Vaccine Revenue Forecast (2021-2026)
12.3.3 Europe: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Inactivated Vaccine Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Inactivated Vaccine Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Inactivated Vaccine Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Inactivated Vaccine Market Size Forecast by Region (2021-2026)
12.5 Latin America Inactivated Vaccine Market Size Forecast (2021-2026)
12.5.1 Latin America: Inactivated Vaccine Sales Forecast (2021-2026)
12.5.2 Latin America: Inactivated Vaccine Revenue Forecast (2021-2026)
12.5.3 Latin America: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Inactivated Vaccine Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Inactivated Vaccine Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Inactivated Vaccine Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Inactivated Vaccine Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Inactivated Vaccine Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Inactivated Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Inactivated Vaccine Market Segments
Table 2. Ranking of Global Top Inactivated Vaccine Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Inactivated Vaccine Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Children
Table 5. Major Manufacturers of Adult
Table 6. COVID-19 Impact Global Market: (Four Inactivated Vaccine Market Size Forecast Scenarios)
Table 7. Opportunities and Trends for Inactivated Vaccine Players in the COVID-19 Landscape
Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 9. Key Regions/Countries Measures against Covid-19 Impact
Table 10. Proposal for Inactivated Vaccine Players to Combat Covid-19 Impact
Table 11. Global Inactivated Vaccine Market Size Growth Rate by Application 2020-2026 (K MT)
Table 12. Global Inactivated Vaccine Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 13. Global Inactivated Vaccine Sales by Regions 2015-2020 (K MT)
Table 14. Global Inactivated Vaccine Sales Market Share by Regions (2015-2020)
Table 15. Global Inactivated Vaccine Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Inactivated Vaccine Sales by Manufacturers (2015-2020) (K MT)
Table 17. Global Inactivated Vaccine Sales Share by Manufacturers (2015-2020)
Table 18. Global Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Inactivated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Inactivated Vaccine as of 2019)
Table 20. Inactivated Vaccine Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Inactivated Vaccine Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Inactivated Vaccine Price (2015-2020) (USD/MT)
Table 23. Inactivated Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Inactivated Vaccine Product Type
Table 25. Date of International Manufacturers Enter into Inactivated Vaccine Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 28. Global Inactivated Vaccine Sales Share by Type (2015-2020)
Table 29. Global Inactivated Vaccine Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Inactivated Vaccine Revenue Share by Type (2015-2020)
Table 31. Inactivated Vaccine Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 32. Global Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 33. Global Inactivated Vaccine Sales Share by Application (2015-2020)
Table 34. North America Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 35. North America Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 36. North America Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 38. North America Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 39. North America Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 40. North America Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 41. North America Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 42. Europe Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 43. Europe Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 44. Europe Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 46. Europe Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 47. Europe Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 48. Europe Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 49. Europe Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Inactivated Vaccine Sales by Region (2015-2020) (K MT)
Table 51. Asia Pacific Inactivated Vaccine Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Inactivated Vaccine Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Inactivated Vaccine Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 55. Asia Pacific Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 57. Asia Pacific Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 58. Latin America Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 59. Latin America Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 62. Latin America Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 63. Latin America Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 64. Latin America Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 65. Latin America Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 67. Middle East and Africa Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 71. Middle East and Africa Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 73. Middle East and Africa Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 74. Astellas Pharma (Japan) Corporation Information
Table 75. Astellas Pharma (Japan) Description and Major Businesses
Table 76. Astellas Pharma (Japan) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Astellas Pharma (Japan) Product
Table 78. Astellas Pharma (Japan) Recent Development
Table 79. CSL Limited (Australia) Corporation Information
Table 80. CSL Limited (Australia) Description and Major Businesses
Table 81. CSL Limited (Australia) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. CSL Limited (Australia) Product
Table 83. CSL Limited (Australia) Recent Development
Table 84. Emergent BioSolutions (U.S.) Corporation Information
Table 85. Emergent BioSolutions (U.S.) Description and Major Businesses
Table 86. Emergent BioSolutions (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Emergent BioSolutions (U.S.) Product
Table 88. Emergent BioSolutions (U.S.) Recent Development
Table 89. GlaxoSmithKline (U.K.) Corporation Information
Table 90. GlaxoSmithKline (U.K.) Description and Major Businesses
Table 91. GlaxoSmithKline (U.K.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. GlaxoSmithKline (U.K.) Product
Table 93. GlaxoSmithKline (U.K.) Recent Development
Table 94. Johnson & Johnson (U.S.) Corporation Information
Table 95. Johnson & Johnson (U.S.) Description and Major Businesses
Table 96. Johnson & Johnson (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Johnson & Johnson (U.S.) Product
Table 98. Johnson & Johnson (U.S.) Recent Development
Table 99. MedImmune (U.S.) Corporation Information
Table 100. MedImmune (U.S.) Description and Major Businesses
Table 101. MedImmune (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. MedImmune (U.S.) Product
Table 103. MedImmune (U.S.) Recent Development
Table 104. Merck & Co (U.S.) Corporation Information
Table 105. Merck & Co (U.S.) Description and Major Businesses
Table 106. Merck & Co (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. Merck & Co (U.S.) Product
Table 108. Merck & Co (U.S.) Recent Development
Table 109. Pfizer (U.S.) Corporation Information
Table 110. Pfizer (U.S.) Description and Major Businesses
Table 111. Pfizer (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Pfizer (U.S.) Product
Table 113. Pfizer (U.S.) Recent Development
Table 114. Sanofi Pasteur (France) Corporation Information
Table 115. Sanofi Pasteur (France) Description and Major Businesses
Table 116. Sanofi Pasteur (France) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Sanofi Pasteur (France) Product
Table 118. Sanofi Pasteur (France) Recent Development
Table 119. Serum Institute of India Pvt (India) Corporation Information
Table 120. Serum Institute of India Pvt (India) Description and Major Businesses
Table 121. Serum Institute of India Pvt (India) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Serum Institute of India Pvt (India) Product
Table 123. Serum Institute of India Pvt (India) Recent Development
Table 124. Global Inactivated Vaccine Sales Forecast by Regions (2021-2026) (K MT)
Table 125. Global Inactivated Vaccine Sales Market Share Forecast by Regions (2021-2026)
Table 126. Global Inactivated Vaccine Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 127. Global Inactivated Vaccine Revenue Market Share Forecast by Regions (2021-2026)
Table 128. North America: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 129. North America: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 130. Europe: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 131. Europe: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 132. Asia Pacific: Inactivated Vaccine Sales Forecast by Region (2021-2026) (K MT)
Table 133. Asia Pacific: Inactivated Vaccine Revenue Forecast by Region (2021-2026) (US$ Million)
Table 134. Latin America: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 135. Latin America: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Middle East and Africa: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 137. Middle East and Africa: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 139. Key Challenges
Table 140. Market Risks
Table 141. Main Points Interviewed from Key Inactivated Vaccine Players
Table 142. Inactivated Vaccine Customers List
Table 143. Inactivated Vaccine Distributors List
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
Table 1. Inactivated Vaccine Market Segments
Table 2. Ranking of Global Top Inactivated Vaccine Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Inactivated Vaccine Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Children
Table 5. Major Manufacturers of Adult
Table 6. COVID-19 Impact Global Market: (Four Inactivated Vaccine Market Size Forecast Scenarios)
Table 7. Opportunities and Trends for Inactivated Vaccine Players in the COVID-19 Landscape
Table 8. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 9. Key Regions/Countries Measures against Covid-19 Impact
Table 10. Proposal for Inactivated Vaccine Players to Combat Covid-19 Impact
Table 11. Global Inactivated Vaccine Market Size Growth Rate by Application 2020-2026 (K MT)
Table 12. Global Inactivated Vaccine Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 13. Global Inactivated Vaccine Sales by Regions 2015-2020 (K MT)
Table 14. Global Inactivated Vaccine Sales Market Share by Regions (2015-2020)
Table 15. Global Inactivated Vaccine Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Inactivated Vaccine Sales by Manufacturers (2015-2020) (K MT)
Table 17. Global Inactivated Vaccine Sales Share by Manufacturers (2015-2020)
Table 18. Global Inactivated Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Inactivated Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Inactivated Vaccine as of 2019)
Table 20. Inactivated Vaccine Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Inactivated Vaccine Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Inactivated Vaccine Price (2015-2020) (USD/MT)
Table 23. Inactivated Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Inactivated Vaccine Product Type
Table 25. Date of International Manufacturers Enter into Inactivated Vaccine Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 28. Global Inactivated Vaccine Sales Share by Type (2015-2020)
Table 29. Global Inactivated Vaccine Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Inactivated Vaccine Revenue Share by Type (2015-2020)
Table 31. Inactivated Vaccine Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 32. Global Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 33. Global Inactivated Vaccine Sales Share by Application (2015-2020)
Table 34. North America Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 35. North America Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 36. North America Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 38. North America Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 39. North America Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 40. North America Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 41. North America Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 42. Europe Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 43. Europe Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 44. Europe Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 46. Europe Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 47. Europe Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 48. Europe Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 49. Europe Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Inactivated Vaccine Sales by Region (2015-2020) (K MT)
Table 51. Asia Pacific Inactivated Vaccine Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Inactivated Vaccine Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Inactivated Vaccine Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 55. Asia Pacific Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 57. Asia Pacific Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 58. Latin America Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 59. Latin America Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 62. Latin America Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 63. Latin America Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 64. Latin America Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 65. Latin America Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Inactivated Vaccine Sales by Country (2015-2020) (K MT)
Table 67. Middle East and Africa Inactivated Vaccine Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Inactivated Vaccine Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Inactivated Vaccine Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Inactivated Vaccine Sales by Type (2015-2020) (K MT)
Table 71. Middle East and Africa Inactivated Vaccine Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Inactivated Vaccine Sales by Application (2015-2020) (K MT)
Table 73. Middle East and Africa Inactivated Vaccine Sales Market Share by Application (2015-2020)
Table 74. Astellas Pharma (Japan) Corporation Information
Table 75. Astellas Pharma (Japan) Description and Major Businesses
Table 76. Astellas Pharma (Japan) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 77. Astellas Pharma (Japan) Product
Table 78. Astellas Pharma (Japan) Recent Development
Table 79. CSL Limited (Australia) Corporation Information
Table 80. CSL Limited (Australia) Description and Major Businesses
Table 81. CSL Limited (Australia) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 82. CSL Limited (Australia) Product
Table 83. CSL Limited (Australia) Recent Development
Table 84. Emergent BioSolutions (U.S.) Corporation Information
Table 85. Emergent BioSolutions (U.S.) Description and Major Businesses
Table 86. Emergent BioSolutions (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 87. Emergent BioSolutions (U.S.) Product
Table 88. Emergent BioSolutions (U.S.) Recent Development
Table 89. GlaxoSmithKline (U.K.) Corporation Information
Table 90. GlaxoSmithKline (U.K.) Description and Major Businesses
Table 91. GlaxoSmithKline (U.K.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 92. GlaxoSmithKline (U.K.) Product
Table 93. GlaxoSmithKline (U.K.) Recent Development
Table 94. Johnson & Johnson (U.S.) Corporation Information
Table 95. Johnson & Johnson (U.S.) Description and Major Businesses
Table 96. Johnson & Johnson (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 97. Johnson & Johnson (U.S.) Product
Table 98. Johnson & Johnson (U.S.) Recent Development
Table 99. MedImmune (U.S.) Corporation Information
Table 100. MedImmune (U.S.) Description and Major Businesses
Table 101. MedImmune (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 102. MedImmune (U.S.) Product
Table 103. MedImmune (U.S.) Recent Development
Table 104. Merck & Co (U.S.) Corporation Information
Table 105. Merck & Co (U.S.) Description and Major Businesses
Table 106. Merck & Co (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 107. Merck & Co (U.S.) Product
Table 108. Merck & Co (U.S.) Recent Development
Table 109. Pfizer (U.S.) Corporation Information
Table 110. Pfizer (U.S.) Description and Major Businesses
Table 111. Pfizer (U.S.) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 112. Pfizer (U.S.) Product
Table 113. Pfizer (U.S.) Recent Development
Table 114. Sanofi Pasteur (France) Corporation Information
Table 115. Sanofi Pasteur (France) Description and Major Businesses
Table 116. Sanofi Pasteur (France) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 117. Sanofi Pasteur (France) Product
Table 118. Sanofi Pasteur (France) Recent Development
Table 119. Serum Institute of India Pvt (India) Corporation Information
Table 120. Serum Institute of India Pvt (India) Description and Major Businesses
Table 121. Serum Institute of India Pvt (India) Inactivated Vaccine Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 122. Serum Institute of India Pvt (India) Product
Table 123. Serum Institute of India Pvt (India) Recent Development
Table 124. Global Inactivated Vaccine Sales Forecast by Regions (2021-2026) (K MT)
Table 125. Global Inactivated Vaccine Sales Market Share Forecast by Regions (2021-2026)
Table 126. Global Inactivated Vaccine Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 127. Global Inactivated Vaccine Revenue Market Share Forecast by Regions (2021-2026)
Table 128. North America: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 129. North America: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 130. Europe: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 131. Europe: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 132. Asia Pacific: Inactivated Vaccine Sales Forecast by Region (2021-2026) (K MT)
Table 133. Asia Pacific: Inactivated Vaccine Revenue Forecast by Region (2021-2026) (US$ Million)
Table 134. Latin America: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 135. Latin America: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Middle East and Africa: Inactivated Vaccine Sales Forecast by Country (2021-2026) (K MT)
Table 137. Middle East and Africa: Inactivated Vaccine Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 139. Key Challenges
Table 140. Market Risks
Table 141. Main Points Interviewed from Key Inactivated Vaccine Players
Table 142. Inactivated Vaccine Customers List
Table 143. Inactivated Vaccine Distributors List
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Inactivated Vaccine Product Picture
Figure 2. Global Inactivated Vaccine Sales Market Share by Type in 2020 & 2026
Figure 3. Children Product Picture
Figure 4. Adult Product Picture
Figure 5. Global Inactivated Vaccine Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital
Figure 7. Medical Center
Figure 8. Inactivated Vaccine Report Years Considered
Figure 9. Global Inactivated Vaccine Market Size 2015-2026 (US$ Million)
Figure 10. Global Inactivated Vaccine Sales 2015-2026 (K MT)
Figure 11. Global Inactivated Vaccine Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Global Inactivated Vaccine Sales Market Share by Region (2015-2020)
Figure 13. Global Inactivated Vaccine Sales Market Share by Region in 2019
Figure 14. Global Inactivated Vaccine Revenue Market Share by Region (2015-2020)
Figure 15. Global Inactivated Vaccine Revenue Market Share by Region in 2019
Figure 16. Global Inactivated Vaccine Sales Share by Manufacturer in 2019
Figure 17. The Top 10 and 5 Players Market Share by Inactivated Vaccine Revenue in 2019
Figure 18. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Inactivated Vaccine Sales Market Share by Type (2015-2020)
Figure 20. Global Inactivated Vaccine Sales Market Share by Type in 2019
Figure 21. Global Inactivated Vaccine Revenue Market Share by Type (2015-2020)
Figure 22. Global Inactivated Vaccine Revenue Market Share by Type in 2019
Figure 23. Global Inactivated Vaccine Market Share by Price Range (2015-2020)
Figure 24. Global Inactivated Vaccine Sales Market Share by Application (2015-2020)
Figure 25. Global Inactivated Vaccine Sales Market Share by Application in 2019
Figure 26. Global Inactivated Vaccine Revenue Market Share by Application (2015-2020)
Figure 27. Global Inactivated Vaccine Revenue Market Share by Application in 2019
Figure 28. North America Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 29. North America Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 30. North America Inactivated Vaccine Sales Market Share by Country in 2019
Figure 31. North America Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 32. U.S. Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 33. U.S. Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Canada Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 35. Canada Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. North America Inactivated Vaccine Market Share by Type in 2019
Figure 37. North America Inactivated Vaccine Market Share by Application in 2019
Figure 38. Europe Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 39. Europe Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. Europe Inactivated Vaccine Sales Market Share by Country in 2019
Figure 41. Europe Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 42. Germany Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 43. Germany Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. France Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 45. France Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. U.K. Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 47. U.K. Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Italy Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 49. Italy Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Russia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 51. Russia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Europe Inactivated Vaccine Market Share by Type in 2019
Figure 53. Europe Inactivated Vaccine Market Share by Application in 2019
Figure 54. Asia Pacific Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 55. Asia Pacific Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 56. Asia Pacific Inactivated Vaccine Sales Market Share by Region in 2019
Figure 57. Asia Pacific Inactivated Vaccine Revenue Market Share by Region in 2019
Figure 58. China Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 59. China Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Japan Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 61. Japan Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. South Korea Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 63. South Korea Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. India Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 65. India Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Australia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 67. Australia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Taiwan Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 69. Taiwan Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Indonesia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 71. Indonesia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Thailand Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 73. Thailand Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Malaysia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 75. Malaysia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Philippines Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 77. Philippines Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Vietnam Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 79. Vietnam Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Asia Pacific Inactivated Vaccine Market Share by Type in 2019
Figure 81. Asia Pacific Inactivated Vaccine Market Share by Application in 2019
Figure 82. Latin America Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 83. Latin America Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 84. Latin America Inactivated Vaccine Sales Market Share by Country in 2019
Figure 85. Latin America Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 86. Mexico Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 87. Mexico Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Brazil Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 89. Brazil Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Argentina Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 91. Argentina Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Latin America Inactivated Vaccine Market Share by Type in 2019
Figure 93. Latin America Inactivated Vaccine Market Share by Application in 2019
Figure 94. Middle East and Africa Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 95. Middle East and Africa Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 96. Middle East and Africa Inactivated Vaccine Sales Market Share by Country in 2019
Figure 97. Middle East and Africa Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 98. Turkey Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 99. Turkey Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Saudi Arabia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 101. Saudi Arabia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. U.A.E Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 103. U.A.E Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Middle East and Africa Inactivated Vaccine Market Share by Type in 2019
Figure 105. Middle East and Africa Inactivated Vaccine Market Share by Application in 2019
Figure 106. Astellas Pharma (Japan) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 107. CSL Limited (Australia) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 108. Emergent BioSolutions (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. GlaxoSmithKline (U.K.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Johnson & Johnson (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. MedImmune (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Merck & Co (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Pfizer (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Sanofi Pasteur (France) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Serum Institute of India Pvt (India) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. North America Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 117. North America Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Europe Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 119. Europe Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Asia Pacific Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 121. Asia Pacific Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Latin America Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 123. Latin America Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Middle East and Africa Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 125. Middle East and Africa Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Porter's Five Forces Analysis
Figure 127. Channels of Distribution
Figure 128. Distributors Profiles
Figure 129. Bottom-up and Top-down Approaches for This Report
Figure 130. Data Triangulation
Figure 131. Key Executives Interviewed
Figure 1. Inactivated Vaccine Product Picture
Figure 2. Global Inactivated Vaccine Sales Market Share by Type in 2020 & 2026
Figure 3. Children Product Picture
Figure 4. Adult Product Picture
Figure 5. Global Inactivated Vaccine Sales Market Share by Application in 2020 & 2026
Figure 6. Hospital
Figure 7. Medical Center
Figure 8. Inactivated Vaccine Report Years Considered
Figure 9. Global Inactivated Vaccine Market Size 2015-2026 (US$ Million)
Figure 10. Global Inactivated Vaccine Sales 2015-2026 (K MT)
Figure 11. Global Inactivated Vaccine Market Size Market Share by Region: 2020 Versus 2026
Figure 12. Global Inactivated Vaccine Sales Market Share by Region (2015-2020)
Figure 13. Global Inactivated Vaccine Sales Market Share by Region in 2019
Figure 14. Global Inactivated Vaccine Revenue Market Share by Region (2015-2020)
Figure 15. Global Inactivated Vaccine Revenue Market Share by Region in 2019
Figure 16. Global Inactivated Vaccine Sales Share by Manufacturer in 2019
Figure 17. The Top 10 and 5 Players Market Share by Inactivated Vaccine Revenue in 2019
Figure 18. Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Inactivated Vaccine Sales Market Share by Type (2015-2020)
Figure 20. Global Inactivated Vaccine Sales Market Share by Type in 2019
Figure 21. Global Inactivated Vaccine Revenue Market Share by Type (2015-2020)
Figure 22. Global Inactivated Vaccine Revenue Market Share by Type in 2019
Figure 23. Global Inactivated Vaccine Market Share by Price Range (2015-2020)
Figure 24. Global Inactivated Vaccine Sales Market Share by Application (2015-2020)
Figure 25. Global Inactivated Vaccine Sales Market Share by Application in 2019
Figure 26. Global Inactivated Vaccine Revenue Market Share by Application (2015-2020)
Figure 27. Global Inactivated Vaccine Revenue Market Share by Application in 2019
Figure 28. North America Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 29. North America Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 30. North America Inactivated Vaccine Sales Market Share by Country in 2019
Figure 31. North America Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 32. U.S. Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 33. U.S. Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 34. Canada Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 35. Canada Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. North America Inactivated Vaccine Market Share by Type in 2019
Figure 37. North America Inactivated Vaccine Market Share by Application in 2019
Figure 38. Europe Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 39. Europe Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 40. Europe Inactivated Vaccine Sales Market Share by Country in 2019
Figure 41. Europe Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 42. Germany Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 43. Germany Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. France Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 45. France Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. U.K. Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 47. U.K. Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. Italy Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 49. Italy Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Russia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 51. Russia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Europe Inactivated Vaccine Market Share by Type in 2019
Figure 53. Europe Inactivated Vaccine Market Share by Application in 2019
Figure 54. Asia Pacific Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 55. Asia Pacific Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 56. Asia Pacific Inactivated Vaccine Sales Market Share by Region in 2019
Figure 57. Asia Pacific Inactivated Vaccine Revenue Market Share by Region in 2019
Figure 58. China Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 59. China Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Japan Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 61. Japan Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. South Korea Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 63. South Korea Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. India Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 65. India Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Australia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 67. Australia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Taiwan Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 69. Taiwan Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Indonesia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 71. Indonesia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Thailand Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 73. Thailand Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Malaysia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 75. Malaysia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Philippines Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 77. Philippines Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Vietnam Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 79. Vietnam Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Asia Pacific Inactivated Vaccine Market Share by Type in 2019
Figure 81. Asia Pacific Inactivated Vaccine Market Share by Application in 2019
Figure 82. Latin America Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 83. Latin America Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 84. Latin America Inactivated Vaccine Sales Market Share by Country in 2019
Figure 85. Latin America Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 86. Mexico Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 87. Mexico Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Brazil Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 89. Brazil Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Argentina Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 91. Argentina Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Latin America Inactivated Vaccine Market Share by Type in 2019
Figure 93. Latin America Inactivated Vaccine Market Share by Application in 2019
Figure 94. Middle East and Africa Inactivated Vaccine Sales Growth Rate 2015-2020 (K MT)
Figure 95. Middle East and Africa Inactivated Vaccine Revenue Growth Rate 2015-2020 (US$ Million)
Figure 96. Middle East and Africa Inactivated Vaccine Sales Market Share by Country in 2019
Figure 97. Middle East and Africa Inactivated Vaccine Revenue Market Share by Country in 2019
Figure 98. Turkey Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 99. Turkey Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Saudi Arabia Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 101. Saudi Arabia Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. U.A.E Inactivated Vaccine Sales Growth Rate (2015-2020) (K MT)
Figure 103. U.A.E Inactivated Vaccine Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Middle East and Africa Inactivated Vaccine Market Share by Type in 2019
Figure 105. Middle East and Africa Inactivated Vaccine Market Share by Application in 2019
Figure 106. Astellas Pharma (Japan) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 107. CSL Limited (Australia) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 108. Emergent BioSolutions (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 109. GlaxoSmithKline (U.K.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Johnson & Johnson (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. MedImmune (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Merck & Co (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Pfizer (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Sanofi Pasteur (France) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Serum Institute of India Pvt (India) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. North America Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 117. North America Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Europe Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 119. Europe Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Asia Pacific Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 121. Asia Pacific Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Latin America Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 123. Latin America Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Middle East and Africa Inactivated Vaccine Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 125. Middle East and Africa Inactivated Vaccine Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Porter's Five Forces Analysis
Figure 127. Channels of Distribution
Figure 128. Distributors Profiles
Figure 129. Bottom-up and Top-down Approaches for This Report
Figure 130. Data Triangulation
Figure 131. Key Executives Interviewed
